Hellebrin and its aglycone form hellebrigenin display similar in vitro growth inhibitory effects in cancer cells and binding profiles to the alpha subunits of the Na+/K+-ATPase

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Moreno Y Banuls, Laetitia ^a   Katz, Adriana ^b   Miklos, Walter ^c   Cimmino, Alessio ^d   Tal, Daniel M ^b   Ainbinder, Elena ^b   Zehl, Martin ^e   Urban, Ernst ^e   Evidente, Antonio ^d   Kopp, Brigitte ^e   Berger, Walter ^c   Feron, Olivier ^f   Karlish, Steven ^b   Kiss, Robert ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Bufadienolides; Cancer; Cardenolides; Cardiotonic steroids; Glycoside aglycone forms; Lactate release oxygen consumption

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AGLYCONE; BUFADIENOLIDE DERIVATIVE; CARDENOLIDE; CARDIAC GLYCOSIDE; CARDIOTONIC AGENT; DIGITOXIN; DIGOXIN; GAMABUFOTALIN RHAMNOSIDE; GITOXIN; HELLEBRIGENIN; HELLEBRIN; LACTIC ACID; OUABAIN; UNCLASSIFIED DRUG; UZARIGENIN RHAMNOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; COLORIMETRY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME PURIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IN VITRO STUDY; MICROSCOPY; MOUSE; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PROTON NUCLEAR MAGNETIC RESONANCE; VIDEOMICROSCOPY;

APOPTOSIS; BUFANOLIDES; CARDIAC GLYCOSIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GLYCOSYLATION; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; ISOENZYMES; LACTIC ACID; METABOLOME; NEOPLASMS; OXIDATION-REDUCTION; OXYGEN CONSUMPTION; PROTEIN BINDING; SODIUM-POTASSIUM-EXCHANGING ATPASE;

STROPHANTHUS GRATUS;

EID: 84880760924     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-33     Document Type: Article

References (58)

1. Pardo LA, Gomez-Varela D, Major F, Sansuk K, Leurs R, Downie BR, Tietze LF, Stühmer W. Approaches targeting Kv10.1 open a novel window for cancer diagnosis and therapy. Curr Med Chem 2012, 19:675-682. 10.2174/092986712798992011, 22204340.
2. Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F, Kiss R. Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta Cancer Rev 2007, 1776:32-57.
3. Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov 2008, 7:926-935. 10.1038/nrd2682, 18948999.
4. Mijatovic T, Dufrasne F, Kiss R. Cardiotonic steroids-mediated targeting of the Na+/K+-ATPase to combat chemoresistant cancers. Curr Med Chem 2012, 19:627-646. 10.2174/092986712798992075, 22204337.
5. Katz A, Lifshitz Y, Bab-Dinitz E, Kapri-Pardes E, Goldshleger R, Tal DM, Karlish SJ. Selectivity of digitalis glycosides for isoforms of human Na, K-ATPase. J Biol Chem 2010, 285:19582-19592. 10.1074/jbc.M110.119248, 2885237, 20388710.
6. Artigas P, Gadsby DC. Ouabain affinity determining residues lie close to the Na/K pump ion pathway. Proc Natl Acad Sci USA 2006, 103:12613-12618. 10.1073/pnas.0602720103, 1567927, 16894161.
7. Liang M, Tian J, Liu L, Pierre S, Liu J, Shapiro J, Xie ZJ. Identification of a pool of non-pumping Na/K-ATPase. J Biol Chem 2007, 282:10585-10593. 10.1074/jbc.M609181200, 17296611.
8. Xie Z, Askari A. Na(+)/K(+)-ATPase as a signal transducer. Eur J Biochem 2002, 269:2434-2439. 10.1046/j.1432-1033.2002.02910.x, 12027880.
9. Wang H, Haas M, Liang M, Cai T, Tian J, Li S, Xie Z. Ouabain assembles signaling cascades through the caveolar Na+/K + -ATPase. J Biol Chem 2004, 279:17250-17259. 10.1074/jbc.M313239200, 14963033.
10. Lefranc F, Mijatovic T, Kondo Y, Sauvage S, Roland I, Debeir O, Krstic D, Vasic V, Gailly P, Kondo S, Blanco G, Kiss R. Targeting the alpha-1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery 2008, 62:211-221. 10.1227/01.NEU.0000311080.43024.0E, 18300910.
11. Liu J, Xie ZJ. The sodium pump and cardiotonic steroids-induced signal transduction protein kinases and calcium-signaling microdomain in regulation of transporter trafficking. Biochim Biophys Acta 1802, 2010:1237-1245.
12. Mijatovic T, Roland I, Van Quaquebeke E, Nilsson B, Mathieu A, Van Vynckt F, Darro F, Blanco G, Facchini V, Kiss R. The alpha-1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 2007, 212:170-179. 10.1002/path.2172, 17471453.
13. Stenkvist B. Is digitalis a therapy for breast carcinoma?. Oncol Rep 1999, 6:493-496.
14. Stenkvist B, Pengtsson E, Dahlquist B, Eriksson O, Jarkrans T, Nordin B. Cardiac glycosides and breast cancer, revisited. N Engl J Med 1982, 306:484.
15. Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA, Stampfer MJ, Willet WC, Giovannucci E, Nelson WG. A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. Cancer Discov 2011, 1:68-77. 10.1158/2159-8274.CD-10-0020, 3227223, 22140654.
16. Mathieu V, Pirker C, Martin de Lasalle E, Vernier M, Mijatovic T, De Neve N, Gaussin JF, Dehoux M, Lefranc F, Berger W, Kiss R. The sodium pump alpha-1 subunit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med 2009, 13:3960-3972. 10.1111/j.1582-4934.2009.00708.x, 19243476.
17. Seligson DB, Rajasekaran SA, Yu H, Liu X, Eeva M, Tze S, Ball W, Horvath S, De Kernion JB, Rajasekaran AK. Na, K-adenosine triphosphatase alpha-1-subunit predicts survival of renal clear cell carcinoma. J Urol 2008, 179:338-345.
18. Sakai H, Suzuki T, Maeda M, Takahashi Y, Horikawa N, Minamimura T, Tsukada K, Takeguchi N. U-regulation of Na+, K + -ATPse alpha-3 isoform and down regulation of the alpha-1 isoform in human colorectal cancer. FEBS Lett 2004, 563:151-154. 10.1016/S0014-5793(04)00292-3, 15063740.
19. Shibuya K, Fukuoka J, Fujii T, Shimoda E, Shimizu T, Sakai H, Tsukada K. Increase in ouabain-sensitive K + -ATPase activity in hepatocellular carcinoma by overexpression of Na+, K + -ATPase alpha-3 isoform. Eur J Pharmacol 2010, 638:42-46. 10.1016/j.ejphar.2010.04.029, 20447393.
20. Cioaca C, Cucu V. Quantitative determination of hellebrin in the rhizomes and roots of Helleborus purpurascens W. et K. Planta Med 1974, 26:250-253. 10.1055/s-0028-1099383, 4427959.
21. Karkare S, Adou E, Cao S, Brodie P, Miller JS, Andrianjafy NM, Razafitsalama J, Andriantsiferana R, Rasamison VE, Kingston DG. Cytotoxic cardenolide glycosides of Roupellina (Strophanthus) boivinii from the Madagascar rainforest. J Nat Prod 2007, 70:1766-1770. 10.1021/np070336n, 2528960, 17988099.
22. Krenn L, Jambrits M, Kopp B. Bufadienolides from Urginea hesperia. Planta Med 1988, 54:227-232. 10.1055/s-2006-962412, 17265257.
23. Krenn L, Ferth R, Robien W, Kopp B. Bufadienolides from Urginea maritime sensu stricto. Planta Med 1991, 57:560-565. 10.1055/s-2006-960206, 17226202.
24. Krenn L, Kopp B, Deim A, Robien W, Kubelka W. About the bufadienolide complex of " Red" Squill. Planta Med 1994, 60:63-69. 10.1055/s-2006-959410, 17236017.
25. Gao H, Zehl M, Kaehlig H, Schneider P, Stuppner H, Moreno Y, Banuls L, Kiss R, Kopp B. Rapid structural identification of cytotoxic bufadienolide sulfates in toad venom from Bufo melanosticus by LC-DAD-MSn and LC-SPE-NMR. J Nat Prod 2010, 73:603-608. 10.1021/np900746k, 20361780.
26. Lifshitz Y, Haviv H, Petrovich E, Tal DM, Goldshleger R, Garty H, Karlish SJ. Purification of the human a2 isoform of Na, K-ATPase expressed in Pichia pastoris. Stabilization by lipids and FXYD1. Biochemistry 2007, 46:14937-14950. 10.1021/bi701812c, 18052210.
27. Yang P, Menter DG, Cartwright C, Chan D, Dixon S, Suraokar M, Mendoza G, Liansa N, Newman RA. Oleandrin-mediated inhibition of human tumor cell proliferation: Importance of Na, K-ATPase alpha subunits as drug targets. Mol Cancer Ther 2009, 8:2319-2328. 10.1158/1535-7163.MCT-08-1085, 19671733.
28. Lin Y, Ho DH, Newman RA. Human tumor cell sensitivity to oleandrin is dependent on relative expression of Na+, K + -ATPAse subunits. J Exp Ther Oncol 2010, 8:271-286.
29. Mathieu A, Remmelink M, D'Haene N, Penant S, Gaussin JF, Van Ginckel R, Darro F, Kiss R, Salmon I. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice. Cancer 2004, 101:1908-1918. 10.1002/cncr.20571, 15386340.
30. Mijatovic T, Mathieu V, Gaussin JF, De Neve N, Ribaucour F, Van Quaquebeke E, Dumont P, Darro F, Kiss R. Cardenolide-induced lysosomal membrane permeabilization contributes therapeutic benefits in experimental human non-small-cell-lung cancers. Neoplasia 2006, 8:402-412. 10.1593/neo.05850, 1592454, 16790089.
31. Branle F, Lefranc F, Camby I, Jeuken J, Geurts-Moespot A, Sprenger S, Sweep F, Kiss R, Salmon I. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p/19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 2002, 95:641-655. 10.1002/cncr.10710, 12209758.
32. van Goietsenoven G, Hutton J, Becker JP, Lallemand B, Robert F, Lefranc F, Pirker C, Vandenbussche G, Van Antwerpen P, Evidente A, Berger W, Prevost M, Pelletier J, Kiss R, Kinzy TG, Kornienko A, Mathieu V. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J 2010, 24:4575-4584. 10.1096/fj.10-162263, 3229423, 20643906.
33. Le Mercier M, Lefranc F, Mijatovic T, Debeir O, Haibe-Kains B, Bontempi G, Decaestecker C, Kiss R, Mathieu V. Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol 2008, 229:172-183. 10.1016/j.taap.2008.01.009, 18313712.
34. Dumont P, Ingrassia L, Rouzeau S, Ribaucour F, Thomas S, Roland I, Darro F, Lefranc F, Kiss R. The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the Death Receptor and/or the mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia 2007, 9:766-776. 10.1593/neo.07535, 1993861, 17898872.
35. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, Reinhold W, Guo Y, Kruh GD, Reimers M, Weinstein JN, Gottesman MM. Predicting drug sensitivity and resistance: Profiling ABC transporter genes in cancer cells. Cancer Cell 2004, 6:129-137. 10.1016/j.ccr.2004.06.026, 15324696.
36. Orina JN, Calcagno AM, Wu CP, Varma S, Shih J, Lin M, Eichler G, Weinstein JN, Pommier Y, Ambudkar SV, Gottesman MM, Gillet TP. Evaluation of current methods used to analyse the expression profiles of ATP-binding cassette transporters yields an improved drug-discovery database. Mol Cancer Ther 2009, 8:2057-2066. 10.1158/1535-7163.MCT-09-0256, 2736804, 19584229.
37. Johnson PH, Walker RP, Jones SW, Stephens K, Meurer J, Zajchowski JA, Luke MM, Eeckman F, Tan Y, Wong L, Parry G, Morgan TK, McCarrick MA, Monforte J. Multiplex gene expression analysis for high-throughput drug discovery: Screening and analysis of compounds affecting genes overexpressed in cancer cells. Mol Cancer Ther 2002, 1:1293-1304.
38. Frese S, Frese-Schaper M, Andres AC, Miescher D, Zumkehr B, Schmid RA. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5. Cancer Res 2006, 66:5867-5874. 10.1158/0008-5472.CAN-05-3544, 16740726.
39. Simpson CD, Mawji IA, Anyiwe K, Williams MA, Wang X, Venugopal AL, Gronda M, Hurren R, Cheng S, Serra S, Behesti-Zavareh R, Datti A, Wrana JL, Ezzat S, Schimmer AD. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoïkis and prevents distant tumor formation. Cancer Res 2009, 69:2739-2747. 10.1158/0008-5472.CAN-08-2530, 19293189.
40. Dong Y, Yin S, Li J, Jiang C, Ye M, Hu H. Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway. Apoptosis 2011, 16:394-403. 10.1007/s10495-011-0573-5, 21259053.
41. Dinara D, Caner S, Kopp B, Opelz G, Terness P. Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol 2003, 3:1791-1801. 10.1016/j.intimp.2003.08.004, 14636829.
42. Juncker T, Cerella C, Teiten MH, Morceau F, Schumacher M, Ghelfi J, Gaascht F, Schnekenburger M, Henry E, Dicato M, Diederich M. UNBS1450, a steroid cardiac glycoside inducing apoptotic cell death in human leukemia cells. Biochem Pharmacol 2011, 81:13-23. 10.1016/j.bcp.2010.08.025, 20849830.
43. Wang Z, Zheng M, Li Z, Li R, Jia L, Xiong X, Southall N, Wang S, Xia M, Austin CP, Zheng W, Xie Z, Sun Y. Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. Cancer Res 2009, 69:6556-6564. 10.1158/0008-5472.CAN-09-0891, 2728080, 19679550.
44. Perne A, Muellner MK, Steinrueck M, Craig-Mueller N, Mayerhofer J, Schwarzinger I, Sloane M, Uras IZ, Hoermann G, Nijman SM, Mayerhoffer M. Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis. PlosOne 2009, 4:e8292.
45. Zhang H, Qian DZ, Tan YS, Lee KA, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1a synthesis and block tumor growth. Proc Natl Acad Sci USA 2008, 105:19579-19586. 10.1073/pnas.0809763105, 2604945, 19020076.
46. Newman RA, Kondo Y, Yokoyama T, Dixon S, Cartwright C, Chan D, Johansen M, Yang P. Autophagic cell death of human pancreatic tumor cells mediated by oleandrin, a lipid-soluble cardiac glycoside. Integr Cancer Ther 2007, 6:354-364. 10.1177/1534735407309623, 18048883.
47. Brouillard F, Tondelier D, Edelman A, Baudouin-Legros M. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells. Cancer Res 2001, 61:1693-1698.
48. Mijatovic T, Jungwirth U, Heffeter P, Hoda MAR, Dornetshuber R, Kiss R, Berger W. The Na+/K + -ATPase is the Achilles Heel of multi-drug-resistant cancer cells. Cancer Lett 2009, 282:30-34. 10.1016/j.canlet.2009.02.048, 19339106.
49. Mijatovic T, Dufrasne F, Kiss R. Na+/K+-ATPase and cancer. Pharm Pat Analyst 2012, 1:91-106.
50. Langenhan JM, Peters NR, Guzei IA, Hoffmann FM, Thorson JS. Enhancing the anticancer properties of cardiac glycosides by neoglycorandomization. Proc Natl Acad Sci USA 2005, 102:12305-12310. 10.1073/pnas.0503270102, 1194917, 16105948.
51. Tian J, Li X, Liang M, Liu L, Xie JX, Ye Q, Kometiani P, Tillekeratne M, Jin R, Xie Z. Changes in sodium pump expression dictate the effects of ouabain on cell growth. J Biol Chem 2009, 284:14921-14929. 10.1074/jbc.M808355200, 2685674, 19329430.
52. Fullerton DS, Kihara M, Deffo T, Kitatsuji E, Ahmed K, Simat B, From AH, Rohrer DC. Cardiac glycosides. 1. A systematic study of digitoxigenin D-glycosides. J Med Chem 1984, 27:256-261. 10.1021/jm00369a004, 6321733.
53. Rathore H, From AH, Ahmed K, Fullerton DS. Cardiac glycosides. 7. Sugar stereochemistry and cardiac glycoside activity. J Med Chem 1986, 29:1945-1952. 10.1021/jm00160a025, 3020248.
54. Hashimoto T, Rathore H, Satoh D, Hong G, Griffin JF, From AH, Ahmed K, Fullerton DS. Cardiac glycosides. 6. Gitoxigenin C16 acetates, formates, methoxycarbonates, and digitoxosides. Synthesis and Na+, K + -ATPase inhibitory activities. J Med Chem 1986, 29:997-1003. 10.1021/jm00156a017, 3012087.
55. Gao H, Popescu R, Kopp B, Wang Z. Bufadienolides and their anticancer activity. Nat Prod Rep 2011, 28:953-969. 10.1039/c0np00032a, 21416078.
56. Liu T, Brown DA, O'Rourke B. Role of mitochondrial dysfunction in cardiac glycoside toxicity. J Mol Cell Cardiol 2010, 49:728-736. 10.1016/j.yjmcc.2010.06.012, 2949492, 20620145.
57. Bers DM. Digitalis and Na/Ca exchange: old dog learns new mitochondrial tricks. J Mol Cell Cardiol 2010, 49:713-714. 10.1016/j.yjmcc.2010.08.004, 2949520, 20708015.
58. Levin D, Harari D, Schreiber G. Stochastic receptor expression determines cell fate upon interferon treatment. Mol Cell Biol 2011, 31:3252-3266. 10.1128/MCB.05251-11, 3147786, 21690295.